FDA Approves Otezla for Psoriatic Arthritis Treatment

The U.S. Food and Drug Administration has approved Otezla (apremilast) for the treatment of psoriatic arthritis in adults.

Advertisement

Manufactured by Summit, N.J.-based Celgene Corp., Otezla demonstrated improvements in symptoms of psoriatic arthritis, such as tender and swollen joints and physical function, in clinical trials.

More Articles on FDA Approvals:

FDA Approves Xolair for Chronic Hives
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.